TY - JOUR
T1 - High-dose therapy with autologous transplantation for Hodgkin's disease
T2 - The Bologna experience
AU - Zinzani, Pier Luigi
AU - Tani, Monica
AU - Gabriele, Annalisa
AU - Gherlinzoni, Filippo
AU - De Vivo, Antonio
AU - Ricci, Paolo
AU - Bandini, Giuseppe
AU - Lemoli, Roberto Massimo
AU - Motta, Maria Rosa
AU - Rizzi, Simonetta
AU - Giudice, Valeria
AU - Zompatori, Maurizio
AU - Stefoni, Vittorio
AU - Alinari, Lapo
AU - Musuraca, Gerardo
AU - Bassi, Simona
AU - Conte, Roberto
AU - Pileri, Stefano
AU - Tura, Sante
AU - Baccarani, Michele
PY - 2003/5/1
Y1 - 2003/5/1
N2 - Background and Objectives. In this work we examine the characteristics and outcome of patients with Hodgkin's disease (HD) treated with high-dose therapy (HDT) and autologous transplantation at our Institute between 1982 to 2000. Design and Methods. A retrospective analysis was performed examining patients' characteristics, prior chemotherapy regimens, pre-transplant disease status, HDT regimen, source of stem cells, time for hematopoietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). Results. Ninety-seven patients with HD were treated and had estimated 10-year OS and RFS rates of 32% and 60%, respectively. Disease status (sensitive vs. refractory) before HDT was the most powerful predictive parameter for OS and RFS in both univariate and multivariate analyses. The rate of transplant-related mortality in the whole cohort was only 1% whereas the rate of second malignancies was 3%. Interpretation and Conclusions. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of HD patients and that the procedure has a very low global early and late toxicity.
AB - Background and Objectives. In this work we examine the characteristics and outcome of patients with Hodgkin's disease (HD) treated with high-dose therapy (HDT) and autologous transplantation at our Institute between 1982 to 2000. Design and Methods. A retrospective analysis was performed examining patients' characteristics, prior chemotherapy regimens, pre-transplant disease status, HDT regimen, source of stem cells, time for hematopoietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). Results. Ninety-seven patients with HD were treated and had estimated 10-year OS and RFS rates of 32% and 60%, respectively. Disease status (sensitive vs. refractory) before HDT was the most powerful predictive parameter for OS and RFS in both univariate and multivariate analyses. The rate of transplant-related mortality in the whole cohort was only 1% whereas the rate of second malignancies was 3%. Interpretation and Conclusions. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of HD patients and that the procedure has a very low global early and late toxicity.
KW - ABMT
KW - Chemotherapy
KW - Hodgkin's disease
KW - Relapse-free survival
UR - http://www.scopus.com/inward/record.url?scp=0038439525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038439525&partnerID=8YFLogxK
M3 - Article
C2 - 12745271
AN - SCOPUS:0038439525
VL - 88
SP - 522
EP - 528
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 5
ER -